A phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: A National Cancer Institute of Canada Clinical Trials Group trial

Investigational New Drugs
M KnowlingElizabeth Eisenhauer

Abstract

BACKGROUND/PATIENTS AND METHODS: 16 adult patients with untreated measurable locally advanced or metastatic inoperable soft tissue sarcoma were treated with oral perifosine, a synthetic alkylphospholipid, believed to inhibit MAP kinase (MAP-K), protein kinase C (PKC), Akt and other regulatory proteins. Perifosine was administered orally in cycles for 21 days out of 28. Loading doses were given day 1 each cycle (900 mg cycle 1, 300 mg cycle 2+) and 150 mg daily was given days 2-21 of each cycle. Cycles were repeated until disease progression, unacceptable toxicity or patient refusal. Seventeen patients were enrolled; 16 and 15 were evaluable for toxicity and response, respectively. A total of 30 cycles of perifosine were administered. Most toxic effects were grade 1 or 2 and commonly included nausea, vomiting, diarrhea, and fatigue (> or =40%). Hematologic toxicity was generally mild. There were no significant biochemical abnormalities due to the drug reported. There were 4 serious adverse events (SAE)-none of which was related to perifosine. No objective responses were seen; 4 patients had stable disease for 1.3 to 8.2 months and the remainder of the patients had progressive disease. Perifosine when given according to this dosi...Continue Reading

References

Mar 1, 1991·Laryngo- rhino- otologie·W J Issing, T P Wustrow
Jun 1, 1994·Journal of Cellular Physiology·A CuadradoC J Molloy
Jun 24, 1999·Journal of Biopharmaceutical Statistics·B ZeeE Eisenhauer
Jan 12, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Urban EmmeneggerKlaus A Neftel
Jul 13, 2002·Expert Review of Anticancer Therapy·Shailendra Verma, Vivien Bramwell
Jul 27, 2002·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M CrulW W ten Bokkel Huinink
Aug 16, 2002·The New England Journal of Medicine·George D DemetriHeikki Joensuu
Sep 5, 2002·International Journal of Cancer. Journal International Du Cancer·Robert G MakiCristina R Antonescu
Aug 15, 2003·The Cochrane Database of Systematic Reviews·V H C BramwellUNKNOWN Sarcoma Disease Site Group
Sep 6, 2003·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J VerweijO S Nielsen
Dec 1, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Lynn Van UmmersenGeorge Wilding
Feb 1, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Grant A McArthurJonathan A Fletcher

❮ Previous
Next ❯

Citations

Apr 29, 2011·Cancer Chemotherapy and Pharmacology·Rebecca G BagleyBeverly A Teicher
Jan 9, 2007·Parasitology Research·María Gabriela Cabrera-SerraJosé E Piñero
Feb 17, 2009·Current Oncology Reports·Joell J Gills, Phillip A Dennis
May 14, 2010·Journal of the National Cancer Institute·Zhijie LiCarol J Thiele
May 16, 2007·Expert Opinion on Investigational Drugs·Aram F Hezel, David P Ryan
Nov 19, 2013·Current Problems in Cancer·Joseph FinneyMarta Batus
Jun 1, 2010·Biochemical Pharmacology·Francisco Muñoz-MartínezFrancisco Gamarro
Aug 9, 2008·European Journal of Obstetrics, Gynecology, and Reproductive Biology·Jörg B EngelJörg Wischhusen
Jun 26, 2007·Experimental Hematology·Laurence CatleyKenneth C Anderson
Feb 9, 2007·Cancer Treatment Reviews·Stefan R VinkMarcel Verheij
Sep 20, 2008·Acta Tropica·M Gabriela Cabrera-SerraJose E Piñero
Aug 14, 2015·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Jie ShenJian-Li Zhang
Feb 17, 2009·Orvosi hetilap·Aron CsehBarna Vásárhelyi
Dec 1, 2010·Biomolecular Concepts·Stacey A SantiHoyun Lee
Dec 14, 2011·Cancer Biology & Therapy·SubbaRao V MadhunapantulaGavin P Robertson
Jan 21, 2015·Pharmacology & Therapeutics·Michael MurrayTristan Rawling
Jun 12, 2016·Pharmacology & Therapeutics·Paul-Alain JaffrèsChristophe Vandier
Sep 18, 2012·Acta Pharmacologica Sinica·Ipsita Pal, Mahitosh Mandal
Apr 27, 2007·Breast Cancer Research and Treatment·Natasha B LeighlMalcolm J Moore
Mar 4, 2009·Zeitschrift für Rheumatologie·I KötterJ B Kümmerle-Deschner
May 5, 2011·Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete·J SchedelI Kötter
Oct 16, 2018·Anti-cancer Agents in Medicinal Chemistry·Ferda KaleağasıoğluMartin R Berger
Jan 1, 2014·Molecular and Cellular Therapies·Amit Kumar, Georges Herbein
Mar 1, 2008·Expert Review of Endocrinology & Metabolism·Kathrin ZitzmannChristoph J Auernhammer
Oct 20, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ruth L VinallRalph W de Vere White
Oct 20, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Brian M Slomovitz, Robert L Coleman
Aug 2, 2007·Anti-cancer Drugs·Jaclyn LoPiccoloPhillip A Dennis
Feb 28, 2017·Biochimica Et Biophysica Acta. Biomembranes·Pablo Ríos-MarcoMaría P Carrasco

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.